Previous close | 66.14 |
Open | 66.03 |
Bid | 65.80 x 100 |
Ask | 84.30 x 200 |
Day's range | 65.68 - 66.09 |
52-week range | 36.99 - 70.81 |
Volume | |
Avg. volume | 145,361 |
Market cap | 1.387B |
Beta (5Y monthly) | 0.80 |
PE ratio (TTM) | 77.75 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.
The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.
Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.